Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Use of T-VEC in early metastatic melanoma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 21.10.18
Views: 1453
Rating:

Ms Viola Franke - Netherlands Cancer Institute, Amsterdam, Netherlands

Viola Franke speaks with ecancer at ESMO 2018 in Munich about results from a trial using engineered virotherapy talimogene laherparepvec (T-VEC) in early metastatic melanoma.

She describes the significant response rates and low toxicity in this early trial, with followups planned to monitor the ongoing survival of these patients.

For more on melanoma news from ESMO, watch our interview with Dr Alexander van Aakooi.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Breast Cancer CDK 4/6


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation